Oxytocin in schizophrenia: a review of evidence for its therapeutic effects
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Background:The suggestion that the neurohormone oxytocin may have clinical application in the treatment of schizophrenia was first published in 1972. Since then, a considerable body of research on a variety of fronts – including several recent double-blind treatment trials – has buttressed these early reports, providing support for the assertion that the oxytocin system is a promising and novel therapeutic target for this devastating malady. Herein, we review the diverse, convergent lines of evidence supporting the therapeutic potential of oxytocin in psychotic illness. Methods:We performed a systematic review of preclinical and clinical literature pertaining to oxytocin's role in schizophrenia. Results:Multiple lines of evidence converge to support the antipsychotic potential of oxytocin. These include several animal models of schizophrenia, pharmacological studies examining the impact of antipsychotics on the oxytocin system, human trials in patients examining the aspects of the oxytocin system and several double-blind, placebo-controlled clinical treatment trials. Conclusions:There exists considerable, convergent evidence that oxytocin has potential as a novel antipsychotic with a unique mechanism of action. Auspiciously, based on the few chronic trials to date, its safety profile and tolerability appear very good. That said, several critical clinical questions await investigation before widespread use is clinically warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690
Biobehavioral responses to stress in females: Tend-and-befriend, not fight-or-flight.
Taylor, S. E., Klein, L. C., Lewis, B. P., Gruenewald, T. L., Gurung, R. A. R., & Updegraff, J. A. (2000) · Psychological Review · doi:10.1037/0033-295x.107.3.411 · Cited by 3,308
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Fett, A.-K. J., Viechtbauer, W., Dominguez, M.-D.-G., Penn, D. L., van Os, J., & Krabbendam, L. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.07.001 · Cited by 1,833
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3044 · Cited by 1,688
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639
Social effects of oxytocin in humans: context and person matter
Bartz, J. A., Zaki, J., Bolger, N., & Ochsner, K. N. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.05.002 · Cited by 1,581 · cited 4×
“effects (152), role of interpersonal stressors in”
BackgroundInfluentialThe environment and schizophrenia
van Os, J., Kenis, G., & Rutten, B. P. F. (2010) · Nature · doi:10.1038/nature09563 · Cited by 1,572 · cited 3×
“the stress-diathesis aspect of the illness (112), and raise the possibility that OT function may distinguish between some of the clinical subtypes (i.”
BackgroundGeyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484 · cited 3×
“Moreover, the PPI disruptions found in patients with schizophrenia can be restored with established antipsychotics, particularly second-generation antipsychotics (130), and schizophrenia-like deficits in PPI can be induced in animals using psychomimetic drugs acting on different neurotransmitter systems of relevance t…”
BackgroundMethodSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Cited by
Neumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954
Cochran, D. M., Fallon, D., Hill, M., & Frazier, J. A. (2013) · Harvard Review of Psychiatry · doi:10.1097/hrp.0b013e3182a75b7d · Cited by 267
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181
Self-citationRutigliano, G., Rocchetti, M., Paloyelis, Y., Gilleen, J., Sardella, A., Cappucciati, M., Palombini, E., Dell’Osso, L., Caverzasi, E., Politi, P., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.117 · Cited by 149
“Administration of OT either intracerebrally or subcutaneously effectively reverted behavioural deficits in rodent models of schizophrenia (Macdonald and Feifel, 2012).”
BackgroundQuintana, D. S., Alvares, G. A., Hickie, I. B., & Guastella, A. J. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.011 · Cited by 149
Metadata
- Authors
- MacDonald, K., & Feifel, D.
- Venue
- Acta Neuropsychiatrica
- Publisher
- Cambridge University Press (CUP)
- Published
- 2012-06
- Volume
- 24
- Issue
- 3
- Pages
- 130-146
- ISSN
- 0924-2708 (ISSN-L)
- 1601-5215
- OpenAlex
- W1976289354
- Cited by
- 111
- References
- 85
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. https://app.cochat.ai/papers/10.1111/j.1601-5215.2011.00634.x
- The paper
- MacDonald, K., & Feifel, D. (2012). Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatrica. https://doi.org/10.1111/j.1601-5215.2011.00634.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.